Nuclera eProtein Discovery System Installed at Leading Academic Institutes
02 May 2024 - 11:36PM
Business Wire
- 11 installs successfully completed
- Novel platform automates and accelerates protein production,
enabling scale-up to mg amount in less than 48 hours
- List of institutes includes, University College London,
University of Cambridge, University of Southampton, University of
Manchester, The Flanders Institute for Biotechnology (VIB) in
Belgium, and the CRUK Cambridge Institute
Nuclera, the biotechnology company accelerating protein
expression and purification workflows through its benchtop protein
system, today announced it has successfully completed 11 installs
of its eProtein Discovery™ system, including at leading academic
institutes. Following the first launch installation at the
University of Southampton1, the system has been placed in academic
institutions including, University College London, University of
Cambridge, University of Manchester, The Flanders Institute for
Biotechnology (VIB) in Belgium, and the CRUK Cambridge
Institute.
Installations of the eProtein Discovery, a protein expression
optimization system, across multiple academic laboratories in the
UK and Europe, follows the Company’s successful Series B financing
round2. With additional installations scheduled throughout 2024,
the commercial launch represents a significant milestone in
providing access to the benchtop automated system.
Custom protein reagents, required in drug discovery, are
challenging to manufacture both in terms of cost and time
associated. The eProtein Discovery platform overcomes this unmet
need by providing rapid access to challenging proteins in a
benchtop system in less than 48 hours. Accelerating drug discovery
processes by up to 30x, the platform provides sequences and optimal
conditions to inform protein manufacturing.
Dr Michael Chen, CEO and co-founder, Nuclera, said: “The
commercial launch of our eProtein Discovery platform and placement
in leading academic institutes marks a key milestone as we bring to
the market a streamlined benchtop solution to accelerate protein
production workflows and ultimately the drug discovery process. By
launching the eProtein Discovery and reaching 11 installations to
date, we are excited to see our technology aid drug development,
enabling new drugs to reach the market faster to help patients with
much-needed treatment.”
For more information about Nuclera’s eProtein Discovery
platform, please visit: https://www.nuclera.com/system/
1. Press release (24th Jan, 2024): A first for the eProtein
Discovery™ System at the University of Southampton
2. Press release (6th Jul, 2022): Nuclera raises additional
capital for eProtein™ desktop bioprinter to close Series B funding
at $58M
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502337758/en/
Dr Ben Rutter Zyme Communications Tel: +44(0)7920 770 935 Email:
ben.rutter@zymecommunications.com